康柏西普治疗慢性中心性浆液性脉络膜视网膜病变继发脉络膜新生血管的疗效及安全性

目的观察康柏西普玻璃体腔注射治疗慢性中心性浆液性脉络膜视网膜病变继发脉络膜新生血管(CSC-CNV)的疗效和安全性。方法采用回顾性病例观察研究,收集2015年9月至2018年1月在温州医科大学附属眼视光医院杭州院区确诊为慢性CSC-CNV的13例14眼患者病例资料,所有患眼均接受玻璃体腔注射0.05 ml/0.5 mg康柏西普治疗,采用1+按需治疗(PRN)方案,观察注射前及注射后1周、1个月、2个月、3个月、6个月时最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)变化。结果6个月随访期内,患眼平均注射次数为(1.93±0.83)次,所有CSC继发的CNV均未突破视网膜色素上皮层。患者玻璃体腔注射前,首次注射后1周、1个月、2个月、3个月和6个月时BCVA分别为0.51±0.32、0.43±0.34、0.36±0.35、0.31±0.28、0.27±0.29和0.26±0.30,CMT值分别为(299.07±132.90)、(216.50±70.94)、(203.00±61.87)、(234.29±95.70)、(194.21±46.46)和(207.43±55.46)μm,总体比较差异均有统计学意义(F=21.225、3.768,均P<0.05);注射后各时间点BCVA均明显优于注射前,CMT值均明显低于注射前,差异均有统计学意义(均P<0.05)。治疗随访期间未出现与治疗相关的严重并发症。结论慢性CSC-CNV患者玻璃体腔注射康柏西普可在短期内降低CMT、提高BCVA,安全性较好。

Efficacy and safety of conbercept for choroidal neovascularization secondary to chronic central serous chorioretinopathy

Objective To evaluate the efficacy and safety of conbercept in patients with choroidal neovascularization secondary to chronic central serous chorioretinopathy(CSC-CNV).Methods A retrospective case study was performed.The medical records of 13 patients(14 eyes)diagnosed as chronic CSC-CNV in Hangzhou Branch of Eye Hospital of Wenzhou Medical University from September 2015 to January 2018 were collected.All the study eyes received intravitreal injection of conbercept(0.05 ml/0.5 mg)under one intravitreal injection and pro re nata(PRN)treatment.The best corrected visual acuity(BCVA)and central macular thickness(CMT)before initial injection and 1 week,1 month,2,3 and 6 months after initial injection were measured and analyzed.This study followed the Declaration of Helsinki and written informed consent was obtained from each patient before initial injection.The study protocol was approved by the Ethics Committee of Hangzhou Branch of Eye Hospital of Wenzhou Medical University(No.2019-029-K-28).Results During the 6-month follow-up,the mean administration times was 1.93±0.83,and all the CNV secondary to CSC did not grow outside the retinal pigment epithelium layer.The BCVA values before initial injection and 1 week,1 month,2,3 and 6 months after initial injection were 0.51±0.32,0.43±0.34,0.36±0.35,0.31±0.28,0.27±0.29 and 0.26±0.30,respectively,with a significant difference among different time points(F=21.225,P<0.05).The BCVA values at each time point after initial injection were significantly better than that before initial injection(all at P<0.05).The CMT values before initial injection and 1 week and 1 month,2,3,6 months after initial injection were(299.07±132.90),(216.50±70.94),(203.00±61.87),(234.29±95.70),(194.21±46.46)and(207.43±55.46)μm,respectively,and the difference was statistically significant among different time points(F=3.768,P<0.05).The CMT values at each time point after initial injection were significantly better than that before initial injection(all at P<0.05).No severe treatment complications were observed during the follow-up period.Conclusions Intravitreal injection of conbercept is safe and can effectively reduce the CMT and improve BCVA of chronic CSC-CNV patients in the short term.